L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders
AssigneesB. G. Negev Technologies and Applications Ltd., At Ben-Gurion University, Moshe Kushnir
InventorsEliahu Heldman, Moshe Kushnir, Eleonora Shaubi
Life of this patent
Estimating the term…
Abstract
The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and/or DOPA decarboxylse inhibitors including, inter alia, L-DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and/or DOPA decarboxylse inhibitor/s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease.
Claims14
A conjugate comprising a sugar molecule and
- two or more L-DOPA molecules,
- wherein said sugar comprises mannitol, glucose, or galactose and wherein said sugar is conjugated via one or more of its hydroxyl groups to the carboxyl group of:
- each of said L-DOPA molecules.
Dependencies are inferred from the claim text.